Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Knowing when to opt for index funds over stocks helps you prioritize diversification and lower maintenance while pursuing gains.
25,835 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Meta Platforms is dialing up AI infrastructure spending, guiding 2026 capex to $125-145 billion after a strong Q1. Th...
Aehr Test Systems faces a pivotal Q4 print after the market closes, with AI burn-in demand and bookings in focus as t...
Mortgage rates sit above 6.6%, yet early 2026 data suggest the housing market still grow. This report breaks down wha...
As quantum dreams grow from labs to law and logistics, Rigetti's domestic footprint and government ties could propel ...
When a top executive sells a sizable stake, investors pay attention. This article unpacks the CFO's 50,000-share move...
As UCB prepares to reveal Q2 results, investors should focus on revenue mix, pipeline progress, and margin resilience...
Senate Democrats allege the White House granted tariff exemptions to firms tied to donors, sparking a bipartisan push...
Investing in builders requires more than chasing growth. This deep dive unpacks why dream finders homes: promising st...
Meta Platforms’ AI push is reshaping sentiment around NVIDIA. This article breaks down what that means for NVIDIA sto...
A new moisture-absorbing paint-and-primer system backed by large homebuilders is entering the market, promising to re...
BYD expands beyond China with a strong EU push, a growing factory footprint, and a multi-region strategy that could r...